Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | SETD1B | Q9UPS6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258310 | 0.83 | NPC1 (0.51) | FBP1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13524043 | 0.82 | NPC1 (0.50) | FBP1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13524042 | 0.80 | NPC1 (0.50) | FBP1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3263056 | 0.79 | NPC1 (0.48) | FBP1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL343717 | 0.77 | KCNMA1 (0.64) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL3958980 | 0.74 | STAT3 (0.45) | LRRK2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3260074 | 0.74 | STAT3 (0.47) | FBP1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13524024 | 0.73 | LMNA (0.50) | LRRK2FBP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6371508 | 0.72 | KMT2A (0.58) | FBP1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL5835776 | 0.70 | CCNE1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789040-A4 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LAB LC (US) | 2009-09-02 | — | — | EP | claimed |
| US-7285567-B2 | Halogenated benzamide derivatives | ROMARK LABORATORIES, L.C. (US) | 2007-10-23 | — | — | US | claimed |
| EP-1789040-A2 | HALOGENATED BENZAMIDE DERIVATIVES | Romark Laboratories, L.C. (US) | 2007-05-30 | — | — | EP | claimed |
| US-20060089396-A1 | Halogenated benzamide derivatives | U.S. BANK NATIONAL ASSOCIATION | 2006-04-27 | — | — | US | claimed |
| WO-2006031566-A2 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LABORATORIES, L.C. (US) | 2006-03-23 | — | — | WO | claimed |
| EP-1789040-B1 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LAB LC (US) | 2015-12-23 | — | — | EP | disclosed |
| US-7645783-B2 | Halogenated benzamide derivatives | ROMARK LABORATORIES L.C. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1789040-A4 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LAB LC (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7550493-B2 | Halogenated benzamide derivatives | ROMARK LABORATORIES, LC (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080097106-A1 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LABORATORIES L.C. . (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096941-A1 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LABORATORIES L.C. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7285567-B2 | Halogenated benzamide derivatives | ROMARK LABORATORIES, L.C. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1789040-A2 | HALOGENATED BENZAMIDE DERIVATIVES | Romark Laboratories, L.C. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060089396-A1 | Halogenated benzamide derivatives | U.S. BANK NATIONAL ASSOCIATION | 2006-04-27 | — | — | US | disclosed |
| WO-2006031566-A2 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LABORATORIES, L.C. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097106-A1 | HALOGENATED BENZAMIDE DERIVATIVES | CBR3, CBR1, HDAC3 | LRRK2 4229/4885FBP1 3380/4885NPC1 884/4885 |
| US-20060089396-A1 | Halogenated benzamide derivatives | CBR3, CBR1, HDAC3 | LRRK2 4201/4885FBP1 3177/4885NPC1 673/4885 |
| US-20080096941-A1 | HALOGENATED BENZAMIDE DERIVATIVES | CBR3, H1-3, BCL3 | LRRK2 4284/4885FBP1 3332/4885NPC1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.